| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 10/23/2023 | 32.11% | Raymond James | $24 → $23 | Maintains | Outperform |
| 07/24/2023 | 26.36% | Stephens & Co. | $20 → $22 | Maintains | Equal-Weight |
| 07/21/2023 | 14.88% | Stephens & Co. | → $20 | Reiterates | Equal-Weight → Equal-Weight |
| 06/16/2023 | 37.85% | Raymond James | $26 → $24 | Maintains | Outperform |
| 04/24/2023 | 49.34% | Raymond James | $28 → $26 | Maintains | Outperform |
| 04/21/2023 | 37.85% | Stephens & Co. | → $24 | Reiterates | → Equal-Weight |
| 04/06/2023 | 60.83% | Raymond James | $36 → $28 | Maintains | Outperform |
| 12/13/2022 | 83.8% | Keefe, Bruyette & Woods | → $32 | Downgrades | Outperform → Market Perform |
| 10/24/2022 | 89.55% | Stephens & Co. | $31 → $33 | Maintains | Equal-Weight |
| 04/22/2022 | 106.78% | Raymond James | $38 → $36 | Maintains | Outperform |
| 01/21/2022 | 118.27% | Raymond James | $34 → $38 | Maintains | Outperform |
| 11/08/2021 | — | Stephens & Co. | Upgrades | Equal-Weight → Overweight | |
| 10/22/2021 | 78.06% | Raymond James | $30 → $31 | Maintains | Outperform |
| 10/07/2021 | 72.31% | Raymond James | $26 → $30 | Maintains | Outperform |
| 08/30/2021 | 72.31% | Piper Sandler | $23 → $30 | Upgrades | Neutral → Overweight |
| 06/03/2021 | 46.47% | Stephens & Co. | → $25.5 | Initiates Coverage On | → Equal-Weight |
| 05/14/2021 | 43.6% | Raymond James | → $25 | Upgrades | Market Perform → Outperform |
| 05/03/2021 | 34.98% | Janney Montgomery Scott | → $23.5 | Upgrades | Neutral → Buy |
| 10/06/2020 | -36.82% | Piper Sandler | → $11 | Initiates Coverage On | → Neutral |
| 05/19/2020 | -19.59% | SunTrust Robinson Humphrey | $16 → $14 | Maintains | Hold |
| 09/13/2019 | 9.13% | Raymond James | → $19 | Downgrades | Outperform → Market Perform |
| 05/30/2019 | — | SunTrust Robinson Humphrey | Downgrades | Buy → Hold | |
| 05/20/2019 | 9.13% | Keefe, Bruyette & Woods | → $19 | Downgrades | Outperform → Market Perform |
| 04/29/2019 | 3.39% | Raymond James | $17 → $18 | Maintains | Outperform |
| 01/16/2019 | -8.1% | SunTrust Robinson Humphrey | → $16 | Initiates Coverage On | → Buy |
| 01/14/2019 | — | Stephens & Co. | Initiates Coverage On | → Equal-Weight | |
| 01/14/2019 | -2.35% | Raymond James | → $17 | Initiates Coverage On | → Outperform |
What is the target price for Amerant Bancorp (AMTB)?
The latest price target for Amerant Bancorp (NYSE: AMTB) was reported by Raymond James on October 23, 2023. The analyst firm set a price target for $23.00 expecting AMTB to rise to within 12 months (a possible 32.11% upside). 9 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Amerant Bancorp (AMTB)?
The latest analyst rating for Amerant Bancorp (NYSE: AMTB) was provided by Raymond James, and Amerant Bancorp maintained their outperform rating.
When is the next analyst rating going to be posted or updated for Amerant Bancorp (AMTB)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Amerant Bancorp, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Amerant Bancorp was filed on October 23, 2023 so you should expect the next rating to be made available sometime around October 23, 2024.
Is the Analyst Rating Amerant Bancorp (AMTB) correct?
While ratings are subjective and will change, the latest Amerant Bancorp (AMTB) rating was a maintained with a price target of $24.00 to $23.00. The current price Amerant Bancorp (AMTB) is trading at is $17.41, which is out of the analyst's predicted range.